- Home
- NQP vs CLLS Comparison
NQP vs CLLS Comparison
Compare NQP & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NQP | CLLS |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.1M | 438.4M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | NQP | CLLS |
|---|---|---|
| Price | $11.88 | $4.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 58.4K | 54.8K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | N/A | $20.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $9.65 | $1.10 |
| 52 Week High | $11.89 | $5.48 |
Technical Indicators
Market Signals| Indicator | NQP | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 39.93 | 50.45 |
| Support Level | $11.83 | $4.02 |
| Resistance Level | $12.10 | $4.17 |
| Average True Range (ATR) | 0.07 | 0.22 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 15.52 | 51.94 |
Price Performance
Historical ComparisonAbout NQP Nuveen Pennsylvania Quality Municipal Income Fund
Nuveen Pennsylvania Quality Municipal Income Fund is a closed-end fixed income mutual fund. The fund's investment objectives are (i) to provide current income exempt from regular federal income tax, the federal alternative minimum tax applicable to individuals and California income tax and (ii) to enhance portfolio value relative to the municipal bond market by investing in tax- exempt municipal securities that the Fund's investment adviser and/or the Fund's sub-adviser, believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The fund prominenty invests in tax-exempt municipal bonds from Pennsylvania that are investment grade.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.